The National Cancer Society Malaysia (NCSM) is sounding an urgent call for policymakers to establish an integrated national co-screening framework designed to prevent, detect and manage cardio-renal-metabolic (CRM) diseases across the country. This push comes amid mounting evidence that these interconnected conditions—encompassing heart disease, kidney disease and metabolic disorders including diabetes—are spreading rapidly through the Malaysian population, with nearly nine in every 10 individuals presenting with two or more CRM risk factors. The convergence of these diseases represents a critical public health challenge that conventional, disease-by-disease approaches have proven inadequate to address.
A landmark screening initiative conducted by NCSM in partnership with Boehringer Ingelheim and support from the Ministry of Health examined 5,000 individuals from disadvantaged communities across the Klang Valley region last year. The findings painted a sobering picture of disease burden in underserved populations. The data revealed that obesity affected 41.3 per cent of screened individuals, while 28.8 per cent were classified as overweight. Pre-diabetic conditions were detected in 34.5 per cent of participants, and 35.1 per cent had already developed diabetes, underscoring a substantial hidden reservoir of undiagnosed or unmanaged blood sugar disorders throughout the community. More alarmingly, 97.8 per cent of all participants carried at least one identifiable CRM risk factor, illustrating how pervasive these health threats have become.
Malaysia's chronic disease landscape has deteriorated noticeably over the past decade, providing additional impetus for systemic reform. Chronic kidney disease prevalence has nearly doubled, climbing from 9.1 per cent in 2011 to 15.5 per cent in 2019. The parallel surge in dialysis-dependent patients is even more striking, with the number requiring regular treatment more than tripling over two decades. These escalating figures represent not only individual health tragedies but also mounting strain on healthcare infrastructure, hospital resources and public expenditure. Without intervention, projections suggest this burden will continue accelerating, potentially overwhelming existing clinical capacity and stretching the sustainability of Malaysia's healthcare financing.
The fundamental problem with existing healthcare delivery structures lies in their fragmented, siloed approach to disease management. Medical systems typically address cardiovascular conditions, kidney disorders and metabolic diseases as separate clinical entities, with different specialists, treatment pathways and monitoring schedules. This compartmentalisation creates dangerous blind spots. Patients may receive treatment for one condition while undiagnosed or untreated risk factors in connected areas go unrecognised, allowing diseases to progress unchecked. Moreover, these conditions genuinely amplify one another—diabetes accelerates kidney damage, kidney dysfunction worsens cardiovascular outcomes, and metabolic dysfunction drives both. Managing them in isolation ignores their synergistic, mutually accelerating nature.
Beyond detection challenges, the patient journey after an abnormal screening result frequently encounters multiple obstacles. Referral pathways between primary care, specialist services and long-term management programmes are often inconsistent or poorly coordinated. Patients who test positive may face delays in receiving appointments, unclear communication about next steps, or weak follow-up mechanisms to ensure they actually reach their treatment appointments. These continuity gaps mean that positive screening results—which should prompt immediate intervention—sometimes lead nowhere, leaving individuals aware of their risk but unable to access timely care. The entire chain from detection to diagnosis to sustained treatment remains fragmented.
NCSM's policy recommendations focus on two interconnected imperatives for national action. First, Malaysia must expand CRM co-screening programmes nationwide, embedding standardised risk assessments into routine health checks rather than maintaining separate screening protocols for different diseases. This integrated approach would enable clinicians to identify multiple overlapping risks within a single consultation, creating opportunities for holistic intervention. Second, the system must strengthen the entire care continuum, ensuring that individuals successfully transition from screening identification through diagnosis, initiation of treatment, and sustained long-term disease management. These recommendations acknowledge that screening alone—detecting problems without ensuring follow-through—represents an incomplete and potentially frustrating intervention.
Implementing these recommendations would require substantial healthcare system redesign. Standardised CRM risk assessment tools would need development and validation for the Malaysian context. Training programmes would be necessary to equip primary care workers with knowledge and skills to conduct integrated screening and interpret results appropriately. Referral protocols would require redesign to connect patients smoothly from community screening to specialist assessment to long-term management pathways. Information systems would need upgrading to track patients across these multiple touchpoints and flag those at risk of losing contact with the healthcare system. The financial investment required would be significant, but advocates argue it pales against the costs of managing preventable disease progression.
Dr Murallitharan Munisamy, Managing Director of NCSM, emphasised the philosophical shift needed in national health strategy. Malaysia has an opportunity to move beyond managing individual diseases in parallel toward treating cardiovascular, kidney and metabolic health as an integrated continuum. This conceptual reframing recognises that these conditions share common root causes—obesity, sedentary lifestyles, dietary patterns, genetic predisposition—and therefore benefit from unified prevention and treatment strategies. Early detection, however, only creates value when matched by coordinated clinical follow-up and long-term management support. Without such continuity, screening programmes become mere exercises in identifying problems without solving them.
The urgency of this moment reflects demographic and epidemiological realities specific to Malaysia's development stage. As the country becomes wealthier and more urbanised, lifestyle risk factors for metabolic and cardiovascular disease proliferate. Aging of the population increases the prevalence of conditions like chronic kidney disease. Existing healthcare infrastructure, while reasonably sophisticated in urban areas, lacks capacity for managing millions of individuals with chronic conditions simultaneously. The window for preventive intervention—identifying people at risk before irreversible organ damage occurs—is narrowing. Each year of delay means more Malaysians progressing from pre-disease states to established disease requiring intensive, expensive management.
Regional context amplifies Malaysia's stakes in this issue. Other Southeast Asian nations face similar epidemiological transitions, and Malaysia's experience could either model successful integrated responses or serve as a cautionary tale of system failure under mounting disease burden. Neighbouring countries monitor Malaysian health policy developments, and successful implementation of comprehensive CRM screening and management could influence regional approaches. Conversely, if Malaysia fails to address these escalating diseases, the region may face a coordinated chronic disease crisis that undermines economic productivity and healthcare system sustainability across Southeast Asia.
The policy briefs launched by NCSM represent an attempt to translate research evidence into actionable government guidance. Such briefs typically succeed only when they gain traction with health officials, finance ministers and political leadership willing to champion systemic change. This requires demonstrating not just clinical efficacy but also financial efficiency—showing that upfront investment in integrated screening and care coordination delivers better health outcomes at lower long-term cost than continuing fragmented, reactive treatment of advanced diseases. The evidence from the Saring@Komuniti Project provides this economic argument, documenting massive hidden disease burden in underserved communities where earlier coordinated intervention could prevent progression.
Implementation will inevitably encounter resistance from multiple directions. Healthcare providers accustomed to treating individual diseases may resist integrated protocols. Budget constraints will create competition between preventive screening programmes and treatment of existing patients. Pharmaceutical companies and medical device manufacturers may have different commercial interests than public health objectives. Building political consensus for sustained investment in prevention—which delivers benefits over years rather than months—competes with pressure for immediate crisis response. Yet the trajectory is clear: without systemic reform toward integrated CRM screening and care, Malaysia faces a future where chronic disease consumes ever-growing shares of healthcare spending while population health outcomes stagnate or decline.
